

## Information Regarding Clinical Trial

<b>Title</b>	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer
<b>Protocol Number</b>	M16-298 (MERU)
<b>Sponsor</b>	AbbVie
<b>Investigator</b>	J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703
<b>Study Related Phone Numbers</b>	479-587-1700 (24 hours)
<b>Key Points for Study</b>	<ul style="list-style-type: none"><li>-Must have achieved clinical benefit to recent 1st-line platinum-based chemo (4 cycles only)</li><li>-At least 3 but no more than 9 wks between C4D1 of platinum-based chemo &amp; randomization</li><li>-<u>Without CNS mets</u>: must be offered PCI, which needs to be completed prior to randomization</li><li>-<u>With hx of CNS mets</u>: documentation of stable/improved</li></ul>